According to STAT News, the FDA is exploring expanded labeling for testosterone therapies to more explicitly include low libido as an approved indication. This development mirrors broader shifts in how regulators view hormone treatments not merely as replacements for clinical deficiency but as tools for sexual wellness and quality-of-life enhancement. However, the original reporting underplays critical context from two decades of fluctuating evidence and fails to connect this move to parallel regulatory softening around anti-aging interventions and the massive direct-to-consumer hormone industry.

The clearest benefits for sexual function come from the Testosterone Trials (TTrials), a coordinated series of seven placebo-controlled RCTs involving 790 men aged 65 and older with unequivocally low testosterone (<275 ng/dL) and symptoms (New England Journal of Medicine, 2016). These government-funded trials (with some pharmaceutical provision of study drug) showed statistically significant but modestly sized improvements in libido and sexual activity (effect size ~0.3–0.45 SD). Benefits were largely confined to men with the lowest baseline levels; men with borderline values saw little gain. Longer-term efficacy and safety beyond one year were not established.

Cardiovascular safety concerns that prompted the FDA's 2015 labeling warnings originated largely from smaller observational studies (e.g., a 2013 JAMA retrospective cohort of 8,709 veterans with low T that reported increased MI risk but suffered from confounding by indication and selection bias). Those fears have been substantially tempered by the TRAVERSE trial, a large industry-supported RCT published in NEJM (2023) that randomized 5,246 men aged 45–80 at high cardiovascular risk to testosterone gel or placebo. The primary cardiovascular endpoint showed no increased risk (HR 0.96, 95% CI 0.81–1.14), though secondary findings included higher rates of pulmonary embolism, atrial fibrillation, and prostate events. Conflicts of interest were notable: the trial was funded by AbbVie and other manufacturers.

What STAT's coverage missed is the downstream effect this label expansion could have on the already booming testosterone telehealth sector. Prescription rates surged over 10-fold between 2000 and 2015 despite stable rates of organic hypogonadism, driven by direct-to-consumer advertising and “low-T” clinics that frequently bypass required diagnostic criteria (two separate morning total T measurements plus consistent symptoms). This regulatory signal, viewed through the lens of the current anti-aging boom (where testosterone is marketed alongside peptides, NAD+, and GLP-1 agonists for “optimization”), risks further medicalizing normal age-related decline. Obesity-driven suppression of the hypothalamic-pituitary-gonadal axis, which accounts for a large fraction of borderline-low T in middle-aged men, is rarely addressed first-line.

Synthesizing the TTrials, TRAVERSE, and Endocrine Society systematic reviews (which rate the evidence for sexual function as moderate-quality), the data support targeted use in symptomatic hypogonadism but provide thin justification for broad libido enhancement in eugonadal or mildly low-T men. Without stricter guardrails—such as mandatory diagnostic confirmation, limits on direct-to-consumer advertising, and mandatory long-term registry studies—the FDA's pivot could expose millions to erythrocytosis, infertility (especially concerning in younger men), prostate stimulation, and unknown decades-long risks while delivering only marginal sexual benefits for many. This decision sits within a larger cultural pattern: as society increasingly rejects unaugmented aging, regulators are being pulled from caution toward accommodation of wellness-driven demand. The real test will be whether post-approval surveillance can prevent the next cycle of overuse and corrective restriction.